Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics Inc (NQ: AGRX )

0.2414 +0.0313 (+14.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agile Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women 
Via News Direct
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Agile Therapeutics: Here's What You Need To Know
 
Via Benzinga
Agile Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Woman-Health Focused Stock Agile Therapeutics Is 'Better Positioned,' Analyst Says While Upgrading Stock
 
Via Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday. 
Via Benzinga
This Biotech Company is Pursuing Positive Cash Flow In 2023
By Margaret Jackson, Benzinga 
Via News Direct
This Biotech Company is Pursuing Positive Cash Flow In 2023
Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023.  
Via Benzinga
Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. 
Via Benzinga
Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla'
 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Why TripAdvisor Shares Are Trading Sharply Lower; Here Are 29 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive,... 
Via Benzinga
NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022
Benzinga Digital Content Studio 
Via News Direct
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling
Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that... 
Via Benzinga
President Biden Mulls Health Emergency For Abortion Access: Report
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
How Does The Abortion Ban Affect Birth Control Stocks?
The debate over abortion reignited in the US following the Supreme Court’s decision to overturn the landmark 1973 Roe v. Wade ruling that generally protects women’s rights to abortion. 
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
U.S Stocks Turn Lower; Dow Tumbles Over 100 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. 
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.